146 related articles for article (PubMed ID: 32426051)
1. A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study.
Ikeda S; Kato T; Kenmotsu H; Ogura T; Iwasawa S; Iwasawa T; Kasajima R; Miyagi Y; Misumi T; Yamanaka T; Okamoto H
Ther Adv Med Oncol; 2020; 12():1758835920922022. PubMed ID: 32426051
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
Ikeda S; Kato T; Kenmotsu H; Ogura T; Sato Y; Hino A; Harada T; Kubota K; Tokito T; Okamoto I; Furuya N; Yokoyama T; Hosokawa S; Iwasawa T; Kasajima R; Miyagi Y; Misumi T; Okamoto H
Oncologist; 2022 Sep; 27(9):720-e702. PubMed ID: 35759340
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis.
Ikeda S; Kato T; Kenmotsu H; Ogura T; Iwasawa S; Sato Y; Harada T; Kubota K; Tokito T; Okamoto I; Furuya N; Yokoyama T; Hosokawa S; Iwasawa T; Yamanaka T; Okamoto H
J Thorac Oncol; 2020 Dec; 15(12):1935-1942. PubMed ID: 32858235
[TBL] [Abstract][Full Text] [Related]
4. Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis.
Ikeda S; Ogura T; Kato T; Kenmotsu H; Iwasawa T; Misumi T; Yamanaka T; Okamoto H
Ther Adv Med Oncol; 2020; 12():1758835920923431. PubMed ID: 32489433
[TBL] [Abstract][Full Text] [Related]
5. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
Asao T; Shukuya T; Mimori T; Goto Y; Tanaka H; Takayama K; Tsubata Y; Tachihara M; Suzuki T; Kaira K; Ko R; Zenke Y; Akamatsu H; Tanizaki J; Ikeda S; Sugawara S; Mizutani H; Mori K; Takahashi K
Clin Lung Cancer; 2023 Nov; 24(7):e247-e253. PubMed ID: 37316381
[TBL] [Abstract][Full Text] [Related]
6. Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia.
Ikeda S; Kato T; Kenmotsu H; Sekine A; Baba T; Ogura T
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439135
[TBL] [Abstract][Full Text] [Related]
7.
Fujimoto K; Ikeda S; Tabata E; Kaneko T; Sagawa S; Yamada C; Kumagai K; Fukushima T; Haga S; Watanabe M; Muraoka T; Sekine A; Baba T; Ogura T
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611005
[TBL] [Abstract][Full Text] [Related]
8. Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study.
Fukuizumi A; Minegishi Y; Omori M; Atsumi K; Takano N; Hisakane K; Takahashi S; Kobayashi K; Sugano T; Takeuchi S; Noro R; Seike M; Kubota K; Azuma A; Gemma A
Int J Clin Oncol; 2019 Dec; 24(12):1543-1548. PubMed ID: 31352631
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
11. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Peters S; Gettinger S; Johnson ML; Jänne PA; Garassino MC; Christoph D; Toh CK; Rizvi NA; Chaft JE; Carcereny Costa E; Patel JD; Chow LQM; Koczywas M; Ho C; Früh M; van den Heuvel M; Rothenstein J; Reck M; Paz-Ares L; Shepherd FA; Kurata T; Li Z; Qiu J; Kowanetz M; Mocci S; Shankar G; Sandler A; Felip E
J Clin Oncol; 2017 Aug; 35(24):2781-2789. PubMed ID: 28609226
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
14. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Shiraishi Y; Kishimoto J; Tanaka K; Sugawara S; Daga H; Hirano K; Azuma K; Hataji O; Hayashi H; Tachihara M; Mitsudomi T; Seto T; Nakagawa K; Yamamoto N; Okamoto I
Clin Lung Cancer; 2020 Sep; 21(5):472-476. PubMed ID: 32381420
[TBL] [Abstract][Full Text] [Related]
15. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
[TBL] [Abstract][Full Text] [Related]
17. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL).
Miura S; Nishio M; Akamatsu H; Goto Y; Hayashi H; Gemma A; Yoshino I; Misumi T; Hata A; Hataji O; Fujita K; Seike M; Yanagitani N; Nishino K; Hara S; Saito R; Mori M; Tsuda T; Iwasawa S; Nakagawa S; Mitsudomi T
JTO Clin Res Rep; 2023 Mar; 4(3):100484. PubMed ID: 37034464
[TBL] [Abstract][Full Text] [Related]
19. Managing Lung Cancer with Comorbid Interstitial Pneumonia.
Ichihara E; Miyahara N; Maeda Y; Kiura K
Intern Med; 2020 Jan; 59(2):163-167. PubMed ID: 31534086
[TBL] [Abstract][Full Text] [Related]
20. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]